After a multiyear low in 2022, China’s cross-border M&A activity experienced a slow recovery in 2023. Although outbound M&A deal value and volume remained lackluster in the first half.
Form F-1 JIUFUYUAN BIOTECHNOLOGY streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
As the People’s Republic of China (PRC) has emerged as a major economic power and competitor, the U.S. has leaned heavily on and enhanced its foreign direct investment regime over.